| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Throughout the last three months, 9 analysts have evaluated American Healthcare REIT (NYSE:AHR), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 6 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts have set 12-month price targets for American Healthcare REIT, revealing an average target of $43.11, a high estimate of $47.00, and a low estimate of $38.00. Surpassing the previous average price target of $38.43, the current average has increased by 12.18%.
The standing of American Healthcare REIT among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Nicholas Yulico | Scotiabank | Raises | Sector Outperform | $47.00 | $42.00 |
| Michael Lewis | Truist Securities | Raises | Buy | $46.00 | $44.00 |
| Michael Lewis | Truist Securities | Raises | Buy | $44.00 | $38.00 |
| Michael Carroll | RBC Capital | Raises | Outperform | $45.00 | $39.00 |
| Aaron Hecht | JMP Securities | Raises | Market Outperform | $45.00 | $40.00 |
| Wesley Golladay | Baird | Announces | Outperform | $41.00 | - |
| Nicholas Yulico | Scotiabank | Announces | Sector Outperform | $42.00 | - |
| Austin Wurschmidt | Keybanc | Raises | Overweight | $40.00 | $34.00 |
| Michael Lewis | Truist Securities | Raises | Buy | $38.00 | $32.00 |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of American Healthcare REIT's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on American Healthcare REIT analyst ratings.
American Healthcare REIT Inc is a healthcare-focused real estate investment trust. It owns a diversified portfolio of clinical healthcare real estate properties, focusing on medical office buildings, skilled nursing facilities, senior housing, hospitals, and other healthcare-related facilities. It has four reportable business segments: integrated senior health campuses, outpatient medical, triple-net leased properties and SHOP. It generates majority of its revenue through Integrated Senior Health Campuses segment.
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, American Healthcare REIT showcased positive performance, achieving a revenue growth rate of 7.52% as of 30 June, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: American Healthcare REIT's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.83%, the company may face hurdles in effective cost management.
Return on Equity (ROE): American Healthcare REIT's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.42%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): American Healthcare REIT's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.22% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.71.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: AHR
